Online, on-demand market research connecting you to the right healthcare stakeholders.
October 26, 2021
Subsequent to a report of a chromosomal abnormality in CAR T-cells in a patient treated in an allogeneic CAR T-cell therapy clinical trial, the FDA has placed a hold on allogeneic CAR T-cell therapy clinical trials being conducted by that company.
InCrowd wanted to understand how this FDA action affected oncologists’ and hematologists’ perceptions of CAR T-cell therapy in both the allogeneic and autologous spaces and gene therapy in general.
Download the latest InCrowd Instant Insights report to learn how 76 US oncologists, hematologists, and hematology-oncologists felt about the future of CAR T-Cell therapy and the impact of FDA actions on their perceptions of gene therapy.
We’d love to show you how physician answers are collected quickly, exceed traditional market research standards, and provide actionable insights.
Our sales team is standing by to help you customize the right program for your business.